These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 8666002)

  • 21. Plasma cholesterol reducing effect of FR129169, a novel acyl-CoA:cholesterol acyltransferase inhibitor, in the rat.
    Sakuma Y; Hagihara H; Ohne K; Nagayoshi A; Mutoh S; Ito Y; Notsu Y; Okuhara M
    Jpn J Pharmacol; 1996 Jan; 70(1):35-41. PubMed ID: 8822087
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A phase I dose-ranging study of the pharmacokinetics, pharmacodynamics, safety, and tolerability of AVN944, an IMPDH inhibitor, in healthy male volunteers.
    Hamilton JM; Harding MW; Genna T; Bol DK
    J Clin Pharmacol; 2009 Jan; 49(1):30-8. PubMed ID: 18971325
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics and safety of escalating single and repeat oral doses of GW420867X, a novel non-nucleoside reverse transcriptase inhibitor.
    Moore KH; Cass LM; Dallow N; Hardman TC; Jones A; Boyce M; Prince WT
    Eur J Clin Pharmacol; 2001; 56(11):805-11. PubMed ID: 11294370
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of the acyl-CoA:cholesterol acyltransferase inhibitor, E5324, on experimental atherosclerosis in rabbits.
    Tanaka H; Ohtsuka I; Kogushi M; Kimura T; Fujimori T; Saeki T; Hayashi K; Kobayashi H; Yamada T; Hiyoshi H
    Atherosclerosis; 1994 Jun; 107(2):187-201. PubMed ID: 7980693
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Correction of dyslipoproteinaemia of casein-fed rabbit by FCE 27677, a potent novel ACAT inhibitor.
    Chiari A; Lovisolo P; Fogliatto G; Fancelli D; Ghiselli G
    Pharmacol Res; 1996 Mar; 33(3):181-9. PubMed ID: 8880889
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of the acyl-CoA:cholesterol acyltransferase inhibitor DuP 128 on cholesterol absorption and serum cholesterol in humans.
    Hainer JW; Terry JG; Connell JM; Zyruk H; Jenkins RM; Shand DL; Gillies PJ; Livak KJ; Hunt TL; Crouse JR
    Clin Pharmacol Ther; 1994 Jul; 56(1):65-74. PubMed ID: 8033496
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ACAT inhibition reverses LCAT deficiency and improves plasma HDL in chronic renal failure.
    Vaziri ND; Liang K
    Am J Physiol Renal Physiol; 2004 Nov; 287(5):F1038-43. PubMed ID: 15280162
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cholesterol-lowering effects of NTE-122, a novel acyl-CoA:cholesterol acyltransferase (ACAT) inhibitor, on cholesterol diet-fed rats and rabbits.
    Azuma Y; Kawasaki T; Ikemoto K; Obata K; Ohno K; Sajiki N; Yamada T; Yamasaki M; Nobuhara Y
    Jpn J Pharmacol; 1998 Nov; 78(3):355-64. PubMed ID: 9869270
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacological properties of YM17E, an acyl-CoA:cholesterol acyltransferase inhibitor, and diarrheal effect in beagle dogs.
    Kashiwa M; Masuyama Y; Miyauchi H; Uchida T; Naganuma S; Kakuta H; Terada M; Kiriyama T; Matsuda K; Ito N; Iizumi Y; Takenaka T
    Jpn J Pharmacol; 1997 Jan; 73(1):41-50. PubMed ID: 9032133
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tolerability, pharmacokinetics and concentration-dependent hemodynamic effects of oral CF101, an A3 adenosine receptor agonist, in healthy young men.
    van Troostenburg AR; Clark EV; Carey WD; Warrington SJ; Kerns WD; Cohn I; Silverman MH; Bar-Yehuda S; Fong KL; Fishman P
    Int J Clin Pharmacol Ther; 2004 Oct; 42(10):534-42. PubMed ID: 15516022
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical pharmacology of DP-b99 in healthy volunteers: first administration to humans.
    Rosenberg G; Angel I; Kozak A
    Br J Clin Pharmacol; 2005 Jul; 60(1):7-16. PubMed ID: 15963088
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Structure-activity relationship of N-[2-(dimethylamino)-6-[3-(5-methyl-4-phenyl-1H-imidazol-1-yl)propoxy] phenyl]-N'-pentylurea and analogues. Novel potent inhibitors of acyl-CoA:cholesterol O-acyltransferase with antiatherosclerotic activity.
    Kimura T; Takase Y; Hayashi K; Tanaka H; Ohtsuka I; Saeki T; Kogushi M; Yamada T; Fujimori T; Saitou I
    J Med Chem; 1993 May; 36(11):1630-40. PubMed ID: 8496930
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacodynamic effects and pharmacokinetics of a new HMG-CoA reductase inhibitor, rosuvastatin, after morning or evening administration in healthy volunteers.
    Martin PD; Mitchell PD; Schneck DW
    Br J Clin Pharmacol; 2002 Nov; 54(5):472-7. PubMed ID: 12445025
    [TBL] [Abstract][Full Text] [Related]  

  • 34. TMP-153, a novel ACAT inhibitor, lowers plasma cholesterol through its hepatic action in golden hamsters.
    Sugiyama Y; Odaka H; Itokawa S; Ishikawa E; Tomari Y; Ikeda H
    Atherosclerosis; 1995 Nov; 118(1):145-53. PubMed ID: 8579624
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibitors of acyl-CoA: cholesterol O-acyl transferase (ACAT) as hypocholesterolemic agents. 6. The first water-soluble ACAT inhibitor with lipid-regulating activity.
    Sliskovic DR; Krause BR; Picard JA; Anderson M; Bousley RF; Hamelehle KL; Homan R; Julian TN; Rashidbaigi ZA; Stanfield RL
    J Med Chem; 1994 Mar; 37(5):560-2. PubMed ID: 8126693
    [No Abstract]   [Full Text] [Related]  

  • 36. Bioavailable acyl-CoA: cholesterol acyltransferase inhibitor with anti-peroxidative activity: synthesis and biological activity of novel indolinyl amide and urea derivatives.
    Kamiya S; Shirahase H; Yoshimi A; Nakamura S; Kanda M; Matsui H; Kasai M; Takahashi K; Kurahashi K
    Chem Pharm Bull (Tokyo); 2000 Jun; 48(6):817-27. PubMed ID: 10866142
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of E5324, a novel inhibitor of acyl-CoA:cholesterol acyltransferase, on cholesteryl ester synthesis and accumulation in macrophages.
    Kogushi M; Tanaka H; Kobayashi H; Yamada T; Ohtsuka I; Kimura T; Saito I
    Jpn J Pharmacol; 1995 Jun; 68(2):191-9. PubMed ID: 7563976
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of food intake on the pharmacokinetic properties of dalcetrapib: findings from three phase I, single-dose crossover studies in healthy volunteers.
    Derks M; Kawamura H; Abt M; Meneses-Lorente G; Phelan M; Ishikawa T
    Clin Ther; 2011 Jun; 33(6):754-65. PubMed ID: 21704240
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibitors of acyl-Coa:cholesterol acyltransferase. 4. A novel series of urea ACAT inhibitors as potential hypocholesterolemic agents.
    Trivedi BK; Holmes A; Stoeber TL; Blankley CJ; Roark WH; Picard JA; Shaw MK; Essenburg AD; Stanfield RL; Krause BR
    J Med Chem; 1993 Oct; 36(22):3300-7. PubMed ID: 8230120
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cholesterol esterification is not essential for secretion of lipoprotein components by HepG2 cells.
    Graham A; Wood JL; Russell LJ
    Biochim Biophys Acta; 1996 Jul; 1302(1):46-54. PubMed ID: 8695654
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.